Reflocibart

瑞伏西拜单抗

Report date: 2023/12/29 11:51:54

Base Information

Drug NameReflocibart
Drug Alias Name2H-10CSL-346
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunomodulatorsVascular endothelial growth factor B inhibitors
TargetsVascular endothelial growth factor B
Therapy Area/IndicationsDiabetic Nephropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPuerto Rico +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCsl Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCsl Behring
Inactive CompaniesN/A
Active IndicationsDiabetic Nephropathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A